About Us

A distinctive investment focus spanning the UK-EU-Africa healthcare innovation corridor. We believe innovation alone does not improve health outcomes. Adoption does.

We recognise that better outcomes require more than breakthrough innovation. They require healthcare systems capable of adopting it. That's why we invest not only in the technologies transforming women's health, but also in the evidence, infrastructure, and care models needed to bring those innovations to scale.

Healthcare was not designed around the realities of women's lives, biology, and health journeys.

The resulting gaps in evidence, diagnosis, treatment, and access have created one of the largest under-addressed markets in healthcare, where significant unmet need converges with substantial opportunities for value creation.

The Challenge

We do not view women's health as a niche category. We view it as a market inefficiency hiding in plain sight and one of the most powerful lenses through which to improve healthcare overall. The challenges exposed in women's health: data gaps, delayed diagnosis, fragmented care pathways, and barriers to adoption, are often the same challenges that limit the effectiveness of healthcare systems more broadly.

The Opportunity

In a truly effective healthcare system, sex-specific needs would be embedded throughout research, product development, clinical practice, and care delivery. The fact that women's health remains a distinct category today reflects not only the work still to be done, but also the scale of the opportunity for innovators capable of delivering better outcomes.

A Better Solution

We therefore invest in both breakthrough technologies and the enabling systems that support their successful adoption; from evidence generation and clinical validation to reimbursement pathways, care delivery models, and healthcare infrastructure. We believe enduring value is created not only by developing better solutions for women, but by building more effective healthcare systems for everyone.

Our approach

How We Invest

The IDEA™ Value Chain

Fern Capital Group invests across the IDEA™ value chain: from generating better health insights to enabling adoption at scale.

IInsightGenerating better understanding through diagnostics, data, AI, and precision health.
DDeliveryImproving how care is accessed, experienced, and delivered across the healthcare journey.
EEnablementBuilding the evidence, infrastructure, reimbursement pathways, and care models required for innovation to scale.
AAdoptionTransforming proven innovation into widespread use, measurable outcomes, and sustainable value creation.

By investing across the full healthcare value chain, from insight to adoption, we seek to accelerate the transition toward more effective, personalised, and sustainable healthcare systems.

Healthcare gaps create opportunity

We invest where healthcare systems fail to capture value and where innovation has the potential to improve outcomes at scale.

1. Better Decisions

We invest in technologies that improve how health is understood, predicted, and diagnosed, enabling earlier intervention, more personalised care, and better clinical decision-making.

Areas of interest include: diagnostics, AI and clinical intelligence, precision health, biomarkers, predictive analytics, and decision-support technologies.

2. Better Care

We back solutions that improve access, outcomes, and patient experience across the healthcare journey — from prevention and primary care to treatment and long-term disease management.

Areas of interest include: reproductive and maternal health, preventive care, chronic and underdiagnosed conditions, digital therapeutics, and innovative care delivery models.

3. Better Adoption

Innovation creates value only when it reaches patients. We invest in the systems that enable healthcare innovation to scale, including clinical validation, reimbursement pathways, care models, and healthcare infrastructure.

Areas of interest include: evidence generation, provider enablement, reimbursement solutions, workflow technologies, healthcare infrastructure, and population health platforms.

Global Outlook. Local Impact.

We invest across established and high-growth markets(across the UK-EU-Africa corridor) where healthcare systems are evolving and opportunities for transformation are greatest. Our global perspective allows us to identify scalable innovations, while our market-specific expertise helps navigate the realities of adoption, regulation, reimbursement, and care delivery. We believe the next generation of healthcare leaders will be those capable of improving outcomes while building systems that enable innovation to reach more people, more effectively.

Our differxnce:

We're purpose-built to invest in women's health.

Specialist Focus

Singular dedication to women's health, with concentrated sector expertise, networks, and capital.

Sector Expertise

Operating and investment experience across life sciences, digital health, and healthcare services.

Commercial Discipline

Focused on clinically validated, scalable models with clear regulatory pathways and revenue viability.

Access Advantage

Differentiated deal flow through early relationships with category-defining founders and operators in women's health.

Cross-Market Perspective

Building businesses positioned to scale across established and high-growth markets globally.

Meet our Leadership team

CO-FOUNDER & GENERAL PARTNER

Dr. Afua Basoah

Neuroscientist, investor, and healthcare strategist with more than 20 years' experience spanning science, healthcare, policy, and capital. Chair of the UK's Centre of Excellence for Women's Health and FemTech, and member of the World Economic Forum's Investor Consortium. Leads Fern Capital Group's investment strategy, capital formation, and ecosystem partnerships, helping translate scientific innovation into routine care.

CO-FOUNDER & GENERAL PARTNER

Dr. Abigail Osei-Kumi

Financial services executive, investor, and governance leader with more than a decade of experience spanning regulated financial services, institutional leadership, and capital deployment. Former Managing Director of a regulated financial institution, where she led organisational growth, governance, and operational transformation. Leads Fern Capital Group's investment management, portfolio development, and governance, backing companies positioned to become part of routine care across diverse healthcare systems

Locally Rooted, Globally Scaled.

Venture Investor

Namira Shabnam

Namira Shabnam has spent five years building a hands-on track record across the full venture capital lifecycle from early-stage diligence and portfolio management through to LP relations and fund modelling. She has worked with both established and debut managers, and her experience spans Africa, Asia, and North America. Namira brings particular depth in sovereign wealth fund relationships and in supporting emerging managers through the structural and strategic demands of fund development.

CEO, Access to Medicine Foundation

Dr Jayasree K. Iyer

Dr Jayasree K. Iyer leads the Access to Medicine Foundation, dedicated to driving systemic change in global healthcare by holding pharmaceutical companies accountable for expanding access to essential medicines. Under her leadership, the Foundation has built the largest health-focused investor signatory network in the world — over 145 signatories managing in excess of $22 trillion in AUM. She speaks regularly at the United Nations, the WHO, and Davos.

SVP Data Scientist, Snowflake

Lucas Catalan-Galan

Lucas Catalan-Galan is a senior data scientist and AI specialist with a track record of delivering award-winning solutions for organisations including Formula 1, the BBC, and Reuters. He brings deep expertise in machine learning, advanced analytics, and the design of user-centred AI tools. A graduate of the University of Warwick with a BA in Philosophy and Politics, Lucas combines technical depth with human-centred thinking.

CEO, Beehane LLC

Hanae Bezad

Hanae Bezad is an impact entrepreneur, investor, board advisor, and author whose work spans government, international development, civil society, and the innovation ecosystem. She is committed to regenerative business models that create lasting value for people, communities, and the planet. Through Beehane LLC and her wider advisory practice, Hanae bridges institutional and grassroots perspectives.

Founder & CEO, Fumena

David Ogundeko

David Ogundeko is a seasoned entrepreneur and investor with over eight years of experience building ventures across Africa. He has constructed and managed a portfolio of more than $100 million across 20+ companies, with deep expertise in SME enablement, last-mile infrastructure, and frontier market liquidity models. David brings practical knowledge of what it takes to build and scale businesses in some of the world's most dynamic markets.

Senior Consultant, Obstetrics, Guy's and St Thomas' NHS Foundation Trust

Professor Eugene Oteng-Ntim

Professor Eugene Oteng-Ntim is a distinguished clinician and academic whose career has broken significant ground in obstetrics and maternal health. He holds the distinction of being the first Black professor at Guy's and St Thomas' and the first Black professor of obstetrics at King's College London. With more than 100 peer-reviewed publications and the presidency of the Royal Society of Medicine's Obstetrics and Gynaecology section.